The PREPARE Pilot randomized controlled trial (RCT) is a multi-center, parallel, blinded RCT that aims to assess the feasibility of a full RCT comparing preoperative very low energy diets (VLEDs) to standard of care prior to elective non-bariatric surgery for obese patients in terms of overall 30-day postoperative morbidity. Adult patients with body mass indices (BMIs) greater than 30 kg/m2 will be randomized 1:1 to receive 3-weeks of preoperative VLED plus preoperative weight loss counselling or preoperative weight loss counselling alone. This trial will enroll patients to assess recruitment, compliance, and follow-up completion to assess the feasibility of a full RCT powered to assess for differences in 30-day postoperative between VLEDs and standard of care arms.
Obesity is a worldwide epidemic affecting upwards of 700 million people. The economic burden in the United States and Canada are estimated at over $2 trillion and $100 billion United States dollars (USD), respectively, and the resultant healthcare consequences can be devastating for systems and patients alike. Obesity is a systemic disease with devastating consequences for patients undergoing any form of operative intervention. Obese patients presenting in need of medical and surgical intervention are at 2-to-6 fold higher risk of prolonged hospitalization, infectious morbidity, venous thromboembolism, and more. To pre-emptively mitigate some of these concerns, prescribed preoperative weight loss via VLEDs has become a standard of care for obese patients undergoing bariatric surgery (i.e., weight loss surgery). While VLEDs have become a standard in obese patients undergoing bariatric surgery, largely due to the significant reduction of peri-organ fat for better visualization, their application to obese patients undergoing other types of surgery remains limited. A previous systematic review and meta-analysis that identified 13 studies evaluating the use of preoperative VLEDs in obese patients undergoing orthopaedic, vascular, colorectal, upper gastrointestinal, gynecological, and a variety of general surgery procedures for benign disease (e.g., cholecystectomy, abdominal wall hernia). While data were heterogenous, preoperative VLEDs reliably resulted in significant weight loss (3.2-19.2kg) with high rates of compliance to the protocols (94-100%). Adverse event rates were low (\<14% in most studies). There were no significant differences in postoperative outcomes, though again pooled analyses included a small number of patients and there were wide corresponding 95% CIs. Overall, this review suggested the evidence for routine use of VLEDs in obese patients undergoing major surgery is compromised by heterogeneous small studies with methodological limitations. A large, definitive trial is required to resolve this uncertainty. Prior to a definitive trial to compare the efficacy of VLEDs in obese patients undergoing major surgery, a pilot RCT is required. A pilot trial will provide the following critical feasibility insights: (1) Assessment of recruitment and randomization ability; (2) Evaluation of compliance to VLED regimens; and (3) Assessment of our ability follow patients completely. The objective of this pilot RCT is to determine the feasibility of a multicenter RCT comparing obese patients (i.e., BMI \> 30kg/m2) receiving VLEDs versus control prior to elective non-bariatric surgery in terms of perioperative outcomes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
88
The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Instructions for use are as follows: 1. Consume 4 Optifast 900 packets each day 2. Take 1 sachet of Optifast 900 once in the morning (AM), once at noon, once in the early evening (PM #1), and once later in the evening (PM #2) for three-weeks. 3. Mix 1 sachet with at least 300 mL (1 1⁄4 cups) of cold water. Shake well or blend in a blender.
Hamilton General
Hamilton, Ontario, Canada
RECRUITINGSt. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
RECRUITINGJuravinski Hospital
Hamilton, Ontario, Canada
RECRUITINGKingston Health Sciences Centre
Kingston, Ontario, Canada
NOT_YET_RECRUITINGRecruitment rate
Defined as the number of patients randomized into the RCT per month.
Time frame: 1 year
Intervention compliance
Defined as the number of preoperative VLED doses taken divided by the total number of doses prescribed for each participant randomized to the intervention arm.
Time frame: 1 year
Follow-up completion
Defined as completion of the pre-VLED, preoperative, and 30-day postoperative visits, along with complete anthropometric measures and study questionnaires.
Time frame: 1 year
Network development
Defined as recruiting from all three participating centers at the aforementioned rate. Additionally, we will aim to extend our multi-disciplinary network to at least 10 centers throughout the course of this pilot RCT in preparation for the full RCT.
Time frame: 1 year
VLED associated adverse events
The primary safety outcome will be all adverse events deemed secondary to the preoperative VLED. The adverse events will be recorded as dichotomous outcomes and described as either minor or serious, similarly to the OPTIWIN Study; the largest medical weight loss RCT evaluating VLEDs.
Time frame: Three-week VLED intervention period.
Overall 30-day postoperative morbidity
This will be defined as any deviation from the usual postoperative course within 30-days of the index operation and will be a composite of system-specific complications.
Time frame: 30-days following index operation.
30-day system-specific complications
Pre-defined system-specific outcomes based on most common postoperative complications following the included types of surgery.
Time frame: 30-days following index operation.
30-day postoperative mortality
Death within 30 days of index surgery.
Time frame: 30-days following index operation.
Preoperative weight loss
Preoperative weight loss will be assessed by measuring the post-VLED weight on the date of surgery and adjusting for the baseline weight in kg.
Time frame: Three-week VLED intervention period.
Operative time
Operative time will be measured as the time between first skin incision and closure of the last surgical wound in minutes and will be retrieved from the patient EMRs.
Time frame: Intraoperative
Intraoperative blood loss
This will be measured in milliliters and will be ascertained from the patient chart.
Time frame: Intraoperative
Surgeon-perceived technical difficulty
Surgeon-perceived difficulty will be evaluated with a short electronic questionnaire administered immediately following completion of the case.
Time frame: Intraoperative
Postoperative length of stay
This will be measured in days and will be ascertained from the patient chart.
Time frame: Through postoperative stay, a mean of 3 days
Health-related quality of life
Utilizing Short Form-36. The lowest and highest possible scores are 0 and 100, respectively. A higher score is associated with a greater health-related quality of life.
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.